Healthcare · head to head
PathAI vs Rx30
PathAI
Healthcare
Digital pathology image management with an FDA cleared platform for primary diagnosis
- From
- On request
- Rated
- -
Rx30
Healthcare
Long-established pharmacy management system for independents and small chains
- From
- On request
- Rated
- -
The short version
- Each has a real cost: PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.; Rx30 shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally
- They diverge on capability: PathAI covers AISight image management, Rx30 covers Prescription processing.
- Prices and features above were last checked on 1 September 2026.
Where they differ
Only the attributes on which PathAI and Rx30 actually diverge.
Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).
What each one covers
Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.
Only in PathAI
- AISight image management
- AISight Dx
- Scanner interoperability
- Case and worklist management
- AI algorithm deployment
- Biopharmaceutical research tooling
- LIS integration
Only in Rx30
- Prescription processing
- Claims adjudication
- Inventory and purchasing
- Point of sale
- Delivery management
- Clinical documentation
What people use each for
The jobs each tool is most often brought in to do.
PathAI
- An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Rx30
- A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Rx30
- A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Rx30
- A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Rx30
Rx30
- Independent pharmacies and small chains wanting a mature, widely-supported systemnot PathAI
- Operations relying on a broad set of wholesaler and PBM interfacesnot PathAI
- Pharmacies with significant front-end retail alongside dispensingnot PathAI
- Multi-store independents needing consistency across locationsnot PathAI
Where each one falls short
Documented limitations, not opinions. Every one is a constraint you would hit in normal use.
PathAI
- AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
- The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
- Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
- Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
- PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.
Rx30
- Shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally
- The interface shows its age against newer entrants, and this is the most common objection in demonstrations
- Pricing is not published, and total cost including hardware and interfaces needs to be requested explicitly
- Windows-centric, with a cloud story less developed than newer competitors
- US-only, tied to US insurance and regulatory requirements
Pricing, plan by plan
PathAI
On request- AISight$undefined/year
- Priced by annual slide or case volume and by pathologist seats
- AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
- Image storage priced by capacity and retention policy
Rx30
On request- Rx30$undefined/month
- Prescription processing
- Claims adjudication
- Inventory
Which should you pick?
Choose Rx30 if
- You need prescription processing.
- You work on Windows, Web.
- You also want claims adjudication.
Questions people ask
- Is PathAI or Rx30 better?
- Neither clearly leads. PathAI starts at On request and Rx30 at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
- Which is cheaper, PathAI or Rx30?
- PathAI starts at On request and Rx30 at On request.
- Does PathAI or Rx30 run on more platforms?
- PathAI runs on Web. Rx30 runs on Windows, Web.
- What is PathAI best used for?
- PathAI is most often used for an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version, a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location, a pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readers, a laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewer. Of those, an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version and a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location are not what Rx30 is typically brought in for.
- What can PathAI do that Rx30 cannot?
- PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management. Rx30 covers Prescription processing, Claims adjudication, Inventory and purchasing, Point of sale.
Answered from the vendors’ own pages
PathAI: What is the difference between AISight and AISight Dx?
AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.
Rx30: Is Rx30 the same company as PioneerRx?
Both are owned by RedSail Technologies. They are sold as separate products to overlapping markets, but roadmap decisions sit with one company, which is worth knowing before treating them as independent options.
PathAI: Can we use our existing scanners?
Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.
Rx30: What does it cost?
Not published. Request the total including hardware, interfaces and training rather than the monthly software fee.
PathAI: Do the AI algorithms carry the same clearance as the platform?
No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.
Rx30: Why do pharmacies stay on it?
Installed base maturity. The interfaces to wholesalers, PBMs and hardware are long established, and those are the things that quietly stop a pharmacy working when they break.
PathAI: Is pricing published?
No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.
Rx30: How does it compare to PioneerRx?
PioneerRx is more aggressively developed around clinical services. Rx30 has the larger legacy base and broader front-end retail heritage. Same owner, different emphasis.
Rx30: Is it suitable for a small chain?
Yes, and that is one of its stronger cases. Multi-store consistency is better handled here than by the systems aimed purely at single independents.
Related pages
Other head to heads
- PathAI vs Techcyte
- PathAI vs Ambra Health
- PathAI vs Paige
- PathAI vs Sysmex
- PathAI vs Sectra
- PathAI vs Lunit
- PathAI vs Aidoc
- PathAI vs Ibex Medical Analytics
- PathAI vs Therapixel
- PathAI vs Gleamer
- PathAI vs Philips IntelliSpace PACS
- PathAI vs Annalise.ai
- PathAI vs Quantum Health
- PathAI vs TherapyNotes
- PathAI vs Zocdoc
- PathAI vs Allscripts Professional EHR
- PathAI vs Liberty Software
- PathAI vs BestRx
- PathAI vs Epic Systems
- PathAI vs Cerner
- PathAI vs Dentrix
- PathAI vs eClinicalWorks
- PathAI vs GoodRx
- PathAI vs Ro
- PathAI vs SilverCloud by Amwell
- PathAI vs OpenClinica
- PathAI vs Bahmni
- PathAI vs Beckman Coulter DxONE
- PathAI vs Carestream Dental
- PathAI vs ChiroTouch
- PathAI vs Cerner PowerChart
- PathAI vs Cerner PowerWorks
- Rx30 vs Techcyte
- Rx30 vs Ambra Health
- Rx30 vs Paige
- Rx30 vs Sysmex
- Rx30 vs Sectra
- Rx30 vs Lunit
- Rx30 vs Aidoc
- Rx30 vs Ibex Medical Analytics
- Rx30 vs Therapixel
- Rx30 vs Gleamer
- Rx30 vs Philips IntelliSpace PACS
- Rx30 vs Annalise.ai
- Rx30 vs Quantum Health
- Rx30 vs TherapyNotes
- Rx30 vs Zocdoc
- Rx30 vs Allscripts Professional EHR
- Rx30 vs Liberty Software
- Rx30 vs BestRx
- Rx30 vs Epic Systems
- Rx30 vs Cerner
- Rx30 vs Dentrix
- Rx30 vs eClinicalWorks
- Rx30 vs GoodRx
- Rx30 vs Ro
- Rx30 vs SilverCloud by Amwell
- Rx30 vs OpenClinica
- Rx30 vs Bahmni
- Rx30 vs Beckman Coulter DxONE
- Rx30 vs Carestream Dental
- Rx30 vs ChiroTouch
- Rx30 vs Cerner PowerChart
- Rx30 vs Cerner PowerWorks